European Association of Urology

The European Association of Urology (EAU) is a non-profit organisation committed to the representation of urology professionals worldwide. All active urology professionals, including urology nurses, are eligible for membership of the EAU. The constituent bodies of the EAU include the: Decisions made by the EAU General Assembly are implemented by the EAU Offices. The Executive Committee and EAU Offices are assisted by the EAU Central Office, which is based in Arnhem, The Netherlands, and run by the Executive Management. The European Academy of Urology is the advisory body to and of the EAU. The Academy consists of members who have previously had official responsibilities within the EAU. The EAU's mission is to raise the level of urological care in Europe by promoting professionalism and competence among our members. The EAU maintains close contacts with national urology organisations who represent the interests of urologists at a national level worldwide.


Some content from Wikipedia, licensed under CC BY-SA

Subscribe to rss feed

Oncology & Cancer

Only through international cooperation can AI improve patient lives

The largest prostate cancer biopsy dataset—involving over 95,000 images—has been created by researchers in Sweden to ensure AI can be trained to diagnose and grade prostate cancer for real world clinical applications.

Health informatics

Machine learning goes with the flow

An artificial intelligence (AI) algorithm trained to listen to patients pass urine is able to identify abnormal flows and could be a useful and cost-effective means of monitoring and managing urology patients at home. It ...

Oncology & Cancer

Gut microbes differ in men with prostate cancer

Researchers have found a significant difference in the gut microbiota of men with prostate cancer, compared with those who have benign biopsies. The study is presented at the European Association of Urology annual congress ...

Oncology & Cancer

New concept drug hunts down late-stage prostate cancer

A new class of drug successfully targets treatment-resistant prostate cancers and prolongs the life of patients. The treatment delivers beta radiation directly to tumor cells, is well tolerated by patients and keeps them ...

page 1 from 8